



SUPPLEMENTARY DATA

Supplementary Figure 1. Study design.



SUPPLEMENTARY DATA

Supplementary Figure 2. Plasma glucose concentration during the stepped hyperglycemic clamp at baseline in type 2 diabetic and nondiabetic subjects. The plasma glucose concentrations during the stepped hyperglycemic clamps performed 48 hours and 14 days after the start of empagliflozin were superimposable to those during the baseline hyperglycemic clamp. * $p < 0.05$ versus baseline (mean of days -5,-4,-2,-1).



SUPPLEMENTARY DATA

Supplementary Table 1. Clinical, laboratory and anthropometric characteristics at baseline. *mean of 4 values on days -5, -4, -2, and -1

	<u>Nondiabetic</u>	<u>Diabetic</u>
Number	15	15
Age (years)	57±2	55±2
Gender (m/f)	10/5	12/3
Weight (kg)	82±3	93±3
BMI (kg/m ²)	28.7±0.8	31.3±1.1
HbA1c (%)	5.6±0.1	7.8±0.2
FPG (mg/dl)	103±2*	195±9*
Diabetes Duration (years)	N/A	8.2±1.6
GFR (ml/min)	139±7*	132±8*
Plasma Na ⁺ (meq/L)	143±0.5	139±1.0
K ⁺ (meq/L)	3.8±0.1	4.2±0.1
Cl ⁻ (meq/L)	105±0.5	102±0.7
Medications (#)		
Metformin		11
Sulfonylurea		1
Met/SU		2
None		1